Kennedy Kenneth, Patel Hetalkumari
UK HealthCare Pharmacy Services, 800 Rose St H-110, Lexington, KY 40536, USA.
Orthopedics. 2011 Dec;34(12):982-5. doi: 10.3928/01477447-20111021-21.
Metastases to the bone are a frequent complication of advanced cancer. Bone metastases have been linked to skeletal-related events, which is the composite endpoint used in clinical trials evaluating therapy to minimize these complications. This article discusses bisphosphonates, which are the historical standard for the prevention of skeletal-related events in patients with metastases from solid tumors and multiple myeloma, and denosumab, which is the first Food and Drug Administration-approved receptor activator of nuclear factor kappa-β ligand (RANKL) inhibitor.
骨转移是晚期癌症常见的并发症。骨转移与骨相关事件有关,骨相关事件是评估治疗以尽量减少这些并发症的临床试验中使用的复合终点。本文讨论了双膦酸盐类药物(其是预防实体瘤和多发性骨髓瘤转移患者骨相关事件的历史标准药物)以及地诺单抗(其是首个获美国食品药品监督管理局批准的核因子κ-β受体活化因子配体(RANKL)抑制剂)。